Every material Form 8-K Labcorp filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Labcorp said on November 4, 2026 that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. A live audio webcast will be available on the company's investor relations website and archived for 180 days, so shareholders can access the remarks. The filing is an administrative disclosure and includes no financial results.
Fireside chat with CFO Julia Wang on November 10, 2026 at 8:45 a.m. ET
Live audio webcast at ir.labcorp.com, archived for replay for 180 days
Press release dated November 4, 2026 furnished as Exhibit 99.1
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from a year earlier, and adjusted EPS of $4.78, up 14.5%. Diluted EPS rose 3.3% to $3.22, and the company raised its full-year 2026 revenue growth and adjusted EPS guidance. For shareholders, the headline measures improved and the higher outlook is the most significant change in the release.
Q3 2026 revenue was $3.81 billion versus $3.56 billion, up 6.9%; organic growth was 5.5%.
Diluted EPS was $3.22 versus $3.12, up 3.3%; adjusted EPS was $4.78 versus $4.18, up 14.5%.
Full-year 2026 adjusted EPS guidance was raised to $18.30 to $18.70 from $18.10 to $18.55; enterprise revenue growth guidance was raised to 5.9% to 6.7%.
Three acquisition agreements were signed after the quarter ended, including Millennium Health and the Myriad Genetics Prenatal Health business, subject to regulatory approvals.
Labcorp's Board of Directors declared a cash dividend of $0.72 per share of common stock, announced October 21, 2026. The dividend is payable December 11, 2026, to holders of record at the close of business on November 24, 2026. The filing contains no earnings, guidance, or other financial results.
Cash dividend of $0.72 per share of common stock declared October 21, 2026
Payable December 11, 2026
Record date is the close of business on November 24, 2026
Labcorp said executive Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will take a broader role effective September 1, 2026, overseeing Biopharma Laboratory Services along with the Early Development Research Laboratories and Central Laboratories businesses.
Megan D. Bailey notified the company of her resignation on August 11, 2026, effective September 4, 2026
Brian J. Caveney, M.D., takes on expanded role effective September 1, 2026
Caveney's new title: EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
The filing does not state a replacement for Bailey's former role or any financial terms
Labcorp reported second-quarter 2026 revenue of $3.73 billion, up 5.8% from a year earlier, and diluted EPS of $3.64, up from $2.84. The company raised its full-year 2026 adjusted EPS guidance to $18.10 to $18.55 and increased its share repurchase authorization by $1.0 billion, leaving $1.4 billion remaining, which points to stronger results and more capital returned to shareholders.
Q2 2026 revenue was $3.73 billion versus $3.53 billion, up 5.8%
Adjusted EPS was $4.99 versus $4.35, up 14.9%; diluted EPS was $3.64 versus $2.84
2026 adjusted EPS guidance raised to $18.10 to $18.55, up 30 cents at the midpoint
Share repurchase authorization increased by $1.0 billion, bringing remaining authorization to $1.4 billion
Labcorp reported first-quarter 2026 revenue of $3.54 billion, up 5.8% from $3.35 billion a year earlier, and diluted EPS of $3.35 versus $2.52. The company raised its full-year 2026 revenue and adjusted EPS guidance, with the adjusted EPS range now $17.70 to $18.35 from $17.55 to $18.25. Headline profit and revenue measures improved, while total debt rose to $6.33 billion at quarter end due to pre-funding of maturing debt.
Q1 2026 revenue $3.54 billion vs. $3.35 billion, up 5.8%; diluted EPS $3.35 vs. $2.52
Q1 2026 adjusted EPS $4.25 vs. $3.84, up 10.6%
Full-year 2026 adjusted EPS guidance raised to $17.70–$18.35 from $17.55–$18.25; revenue guidance raised to 5.0%–6.1% growth
Quarterly dividend of $0.72 per share declared April 9, 2026, payable June 11, 2026 to holders of record May 29, 2026
Labcorp and its subsidiary Laboratory Corporation of America Holdings signed a $750 million senior unsecured term loan with Wells Fargo as administrative agent, fully funded on March 20, 2026. The loan matures March 20, 2028 and carries a floating rate of SOFR plus 0.700% or a base rate with a 0% margin. It adds to the company's debt obligations and includes a leverage ratio covenant of 4.0 to 1.0.
$750 million senior unsecured term loan, fully funded on March 20, 2026
Matures March 20, 2028; floating rate of SOFR plus 0.700% or base rate plus 0%
Leverage ratio covenant of not more than 4.0 to 1.0, with a temporary increase to 4.5 to 1.0 allowed after a material acquisition
Wells Fargo Bank, National Association is administrative agent; PNC Bank, National Association is syndication agent
Labcorp reported fourth-quarter 2025 revenue of $3.52 billion, up from $3.33 billion, and full-year revenue of $13.95 billion, up from $13.01 billion. Full-year diluted EPS rose to $10.46 from $8.84, and the company provided 2026 guidance calling for adjusted EPS of $17.55 to $18.25, compared with $16.44 in 2025. Fourth-quarter restructuring and other charges of $110.8 million, up from $11.4 million a year earlier, were a notable offsetting item.
Q4 2025 diluted EPS was $1.98 vs $1.70 a year earlier; Q4 adjusted EPS was $4.07 vs $3.45
2026 guidance: revenue of $14.61 billion to $14.79 billion and free cash flow of $1.24 billion to $1.36 billion
Q4 2025 free cash flow was $490.3 million vs $665.1 million, which the company attributed to working capital timing
Quarterly dividend of $0.72 per share is payable March 12, 2026, to holders of record on February 27, 2026
Labcorp Holdings appointed John H. Sampson, M.D., Ph.D., as a board member effective February 9, 2026, and named him to the Quality and Compliance Committee. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. The filing describes a board addition with no financial results, guidance or deal terms attached.
Board appointment effective February 9, 2026; Board approved the appointment on February 6, 2026
Sampson joins the Quality and Compliance Committee
Sampson will receive director compensation under the company's program described in its April 4, 2025 proxy statement
Sampson is vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine
Labcorp amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date to January 26, 2029. The amendment adds a committed $125 million accordion that lets the subsidiary raise the facility limit from $700 million to up to $825 million on or before May 29, 2026. The filing describes this as a financing update rather than a change in operating results.
Scheduled termination date extended to January 26, 2029
Committed $125 million accordion lets facility limit rise from $700 million to up to $825 million by May 29, 2026
Removed the 0.10% SOFR adjustment previously added to capital accruing yield
Labcorp Receivables assets are not available to pay Labcorp's other creditors
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Labcorp filing is on SEC EDGAR ↗. 8-K briefs of other companies →